News

During a live event, Andrew Brunner, MD, and participants discussed escalating therapy in luspatercept-refractory LR-MDS.

During a live event, Matthew Rettig, MD, and participating oncologists discussed a case of a 74-year-old man with metastatic hormone-sensitive prostate cancer.

FDA issues CRL for Ga-68 edotreotide NET PET kit, citing third-party manufacturing; decentralized SSTR imaging promise remains pending.

After 2 prior CRLs, the FDA accepted a resubmitted BLA as a complete class 1 response with a goal date of August 2, 2026 for the oncolytic therapy for melanoma.

Genetic testing isn’t the finish line—learn how evolving risk models, dense breast guidance, and MCED screening may transform early cancer detection.

FDA clears BESREMi Pen, adding a simpler self-injection choice for adults with polycythemia vera on long-term ropeginterferon therapy.

TRIDENT shows early TTFields with chemoradiation doesn’t boost survival in newly diagnosed glioblastoma, but remains feasible with stable safety.

MammaPrint in the FLEX registry predicts which HR+/HER2– early breast cancers benefit from anthracyclines—guiding safer, personalized chemo.

Experts debate tivozanib’s durable responses and tolerability after immunotherapy in metastatic RCC, shaping smarter VEGFR-TKI sequencing.

Heather J. Landau, MD, discussed promising results of CAR T-cell therapy in light chain amyloidosis and the challenge of developing trials for this rare plasma cell disorder.

Myriad’s Precise MRD expands to breast, colorectal and renal cancers, using serial ctDNA tracking to spot residual disease and predict response.

During a live event, Gurbakhash Kaur, MD, and Donna Catamero, ANP-BC, OCN, CCRC, and participants discussed frontline treatment selection, duration of therapy, and the emerging role of MRD-guided decision-making in newly diagnosed multiple myeloma.

Ranjit Goudar, MD explains how community oncology practices are expanding hereditary cancer care through genetic testing, workflow redesign, and personalized prevention strategies.

NCCN adds ctDNA-MRD testing after cystectomy, using Signatera to identify MIBC patients who may benefit from adjuvant atezolizumab.

During a live event, Kristen M. Pettit, MD, discussed the potential of using treatment earlier in polycythemia vera to alter the disease course.

During a live event, Julia Rotow, MD, and participants discussed how community oncologists are managing chemotherapy-induced neutropenia in extensive-stage small cell lung cancer.

FDA approves sacituzumab govitecan-hziy alone or with pembrolizumab as first-line therapy for unresectable/metastatic triple-negative breast cancer.

FDA approves palbociclib plus trastuzumab, with/without pertuzumab, and endocrine therapy as maintenance for HR+, HER2+ advanced breast cancer.

Long-term follow-up from IMROZ included findings on MRD dynamics with quadruplet frontline therapy in multiple myeloma.

Early phase 2 results suggest 12-cycle pirtobrutinib–obinutuzumab yields high responses in untreated CLL with minimal cardiac effects.

It was previously shown that the STELLAR-303 trial achieved the coprimary end point of OS in the ITT population.

Results from the SPEARHEAD-1 trial supported FDA approval of the engineered T-cell product for patients as young as 12 years of age.

The investigational ADC sigvotatug vedotin missed the primary OS endpoint vs docetaxel in phase 3 NSCLC trial, but showed stronger second-line benefit trends.

During a live event, Christopher Lieu, MD, and participants discussed selecting third-line therapy for KRAS-mutant metastatic colorectal cancer.

Dr Haigentz breaks down 3 practice-changing ASCO 2026 lung cancer abstracts, from adjuvant targeted therapy to ADCs reshaping the immunotherapy backbone.

Glioblastoma treatment still stalls beyond Stupp, while meningioma lacks systemic salvage options; Singh highlights adaptive trials, molecular profiling, and young-patient quality-of-life risks.

An ongoing dose expansion phase of the trial is evaluating CRB-701 plus pembrolizumab for first-line OPSCC.

Blood-based T‑cell receptor sequencing reveals immune “fingerprints” in Lynch syndrome, helping track precancers early and paving the way for new cancer surveillance biomarkers.